Your browser doesn't support javascript.
loading
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade.
Motzer, Robert J; Banchereau, Romain; Hamidi, Habib; Powles, Thomas; McDermott, David; Atkins, Michael B; Escudier, Bernard; Liu, Li-Fen; Leng, Ning; Abbas, Alexander R; Fan, Jinzhen; Koeppen, Hartmut; Lin, Jennifer; Carroll, Susheela; Hashimoto, Kenji; Mariathasan, Sanjeev; Green, Marjorie; Tayama, Darren; Hegde, Priti S; Schiff, Christina; Huseni, Mahrukh A; Rini, Brian.
Afiliación
  • Motzer RJ; Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: motzerr@mskcc.org.
  • Banchereau R; Oncology Biomarker Development, Genentech, Inc, South San Francisco, CA 94080, USA.
  • Hamidi H; Oncology Biomarker Development, Genentech, Inc, South San Francisco, CA 94080, USA.
  • Powles T; Barts Cancer Institute and the Royal Free Hospital, Queen Mary University of London, London, UK.
  • McDermott D; Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Atkins MB; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.
  • Escudier B; Gustave Roussy, Villejuif, France.
  • Liu LF; Oncology Biomarker Development, Genentech, Inc, South San Francisco, CA 94080, USA.
  • Leng N; Oncology Biomarker Development, Genentech, Inc, South San Francisco, CA 94080, USA.
  • Abbas AR; Oncology Biomarker Development, Genentech, Inc, South San Francisco, CA 94080, USA.
  • Fan J; Oncology Biomarker Development, Genentech, Inc, South San Francisco, CA 94080, USA.
  • Koeppen H; Oncology Biomarker Development, Genentech, Inc, South San Francisco, CA 94080, USA.
  • Lin J; Oncology Biomarker Development, Genentech, Inc, South San Francisco, CA 94080, USA.
  • Carroll S; Calithera Biosciences, Inc, South San Francisco, CA, USA.
  • Hashimoto K; Crescendo Biologics, Inc, Cambridge, UK.
  • Mariathasan S; Oncology Biomarker Development, Genentech, Inc, South San Francisco, CA 94080, USA.
  • Green M; Oncology Biomarker Development, Genentech, Inc, South San Francisco, CA 94080, USA.
  • Tayama D; Oncology Biomarker Development, Genentech, Inc, South San Francisco, CA 94080, USA.
  • Hegde PS; Foundation Medicine, Cambridge, MA, USA.
  • Schiff C; Oncology Biomarker Development, Genentech, Inc, South San Francisco, CA 94080, USA.
  • Huseni MA; Oncology Biomarker Development, Genentech, Inc, South San Francisco, CA 94080, USA. Electronic address: huseni.mahrukh@gene.com.
  • Rini B; Vanderbilt University Medical Center, Nashville, TN, USA.
Cancer Cell ; 38(6): 803-817.e4, 2020 12 14.
Article en En | MEDLINE | ID: mdl-33157048
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores de Tumor / Inhibidores de la Angiogénesis / Inhibidores de Puntos de Control Inmunológico / Neoplasias Renales Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Cancer Cell Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores de Tumor / Inhibidores de la Angiogénesis / Inhibidores de Puntos de Control Inmunológico / Neoplasias Renales Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Cancer Cell Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article